

<i>Authors &amp; date &amp; location &amp; review type</i>	<i>Review methods:</i>				<i>Review results:</i>					<i>Conclusion</i>
	<i>Eligibility criteria</i>	<i>Risk of bias</i>	<i>Summary measure</i>	<i>Synthesis of results</i>	<i>Study characteristics</i>	<i>Risk of bias</i>	<i>Synthesis of results</i>	<i>Narrative summary</i>	<i>Adverse reactions</i>	
Write review type here: meta-analysis or systematic review	Criteria for including studies in the review	How was the risk of bias calculated for each study	Only applicable for meta-analysis: What is the principal study measure? i.e. change in score on the standardised rating scale for depression from baseline to post infusion with either ketamine or placebo	Only applicable for meta-analysis: How were the results calculated? For instance using relative risk ratios or odds ratios etc.	Briefly describe the characteristics of studies included in the review. Study design. Number, age, gender, diagnosis of patients included if available. See Lee et al., 2015 (Ketamine as a novel treatment for major depressive disorder and bipolar depression), section Study Characteristics as an example	Describe the results of risk of bias analysis of individual studies. See same study (Lee et al., 2015) for an example	Only for meta-analysis. Summarise the result of meta-analysis. See Lee et al., 2015 for example	Briefly summarise the results narratively. Use the discussion section of the review for this rather than going through results of individual studies. Only summarise results relating to primary and secondary outcomes of systematic review.	Report any adverse reactions in the review.	Summarise in 2-3 sentences main conclusions from the review.

This form is associated with the following publication:

Walsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B. R., Nutt, D. J., Morgan, C. J. A. (In Press). Ketamine for the Treatment of mental health and substance use disorders: a comprehensive systematic review. *BJ Psych Open*.